ArticleClinical orthopaedics and related research2016
Biofilm Antimicrobial Susceptibility Increases With Antimicrobial Exposure Time.
Article in Clinical orthopaedics and related research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 134 citations in OpenAlex.
- Effect on total microbial load and community composition with two vs six-week topical Cadexomer Iodine for treating chronic biofilm infections in diabetic foot ulcers.International wound journal · 2019Trial
- Local antibiotic treatment for periprosthetic joint infection: current approaches and the emerging role of continuous local antibiotic perfusion.International orthopaedics · 2026Review
- When Culture Results Don't Tell the Whole Story: A Practical Review of Antibiotics Pitfalls for Clinical Decision-Making.Infectious diseases and therapy · 2026Review
- Characterising the Antimicrobial Performance of Engineered Layered Double Hydroxide Surfaces for Biofilm Control.Nanomaterials (Basel, Switzerland) · 2026Article
- Soil-Dwelling Bacteria Display Tolerance Against Typical Antibiotic Serum Levels in an Ex Vivo Model of Traumatized Tissue.Military medicine · 2026Article
- Polyhexanide, Povidone-Iodine, and Hypochlorous Acid Show High In Vitro Antimicrobial Efficacy Against Pathogens Commonly Associated With Equine Infectious Keratitis.Veterinary ophthalmology · 2026Article
- Hypertonic thermal solutions as a putative strategy for respiratory biofilm disruption.Open medicine (Warsaw, Poland) · 2026Article
- Emerging Multimodal Strategies for Bacterial Biofilm Eradication: A Comprehensive Review.Microorganisms · 2025Review
- A semi-solid in vitro biofilm model for evaluating antimicrobial potency and biofilm-specific activity.Biofilm · 2025Article
- Chlorpromazine, impregnated in foley catheter fragments, as an antibiofilm agent to control urinary tract infections.Future microbiology · 2025Article
- Novel Insights Into the Struggle Against Biofilm: The PsyOmp38 Protein From the Antarctic Marine Bacterium Psychrobacter sp. TAE2020.Microbial biotechnology · 2025Article
- UropathogenicInternational journal of molecular sciences · 2025Article
- Biocides as drivers of antibiotic resistance: A critical review of environmental implications and public health risks.Environmental science and ecotechnology · 2025Review
- Toward essential oil stewardship: strain-resolved evaluation of thyme oil activity againstFrontiers in pharmacology · 2025Article
- Effective biofilm eradication in MRSA isolates with aminoglycoside-modifying enzyme genes using high-concentration and prolonged gentamicin treatment.Microbiology spectrum · 2024Article
- Alkyl Pyridinol Compounds Exhibit Antimicrobial Effects against Gram-Positive Bacteria.Antibiotics (Basel, Switzerland) · 2024Article
- Designed De Novo α-Sheet Peptides Destabilize Bacterial Biofilms and Increase the Susceptibility ofInternational journal of molecular sciences · 2024Article
- DAIR in treating chronic PJI after total knee arthroplasty using continuous local antibiotic perfusion therapy: a case series study.BMC musculoskeletal disorders · 2024Article
- Clinical use and applications of a citrate-based antiseptic lavage for the prevention and treatment of PJI.Frontiers in medicine · 2024Article
- A microtiter peg lid with ziggurat geometry for medium-throughput antibiotic testing andBiofilm · 2023Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe antimicrobial concentration required to kill all the bacteria in a biofilm, known as the minimum biofilm eradication concentration (MBEC), is typically determined in vitro by exposing the biofilm to serial concentrations of antimicrobials for 24 hours or less. Local delivery is expected to cause high local levels for longer than 24 hours. It is unknown if longer antimicrobial exposures require the same concentration to eradicate bacteria in biofilm. Questions/purposes Does MBEC change with increased antimicrobial exposure time?
methodsBiofilms were grown for 24 hours using five pathogens (methicillin-sensitive Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, and Pseudomonas aeruginosa) and then exposed to four antimicrobials regimens: tobramycin, vancomycin, and tobramycin combined with vancomycin in 3:1 and 1:1 ratios by weight in concentrations of 62.5, 125, 250, 500, 1000, 2000, 4000, and 8000 μg/mL for three durations, 1, 3, and 5 days, in triplicate. MBEC was measured as the lowest concentration that killed all bacteria in the biofilm determined by 21-day subculture.
resultsMBEC was lower when antimicrobial exposure time was longer. For the staphylococcus species, the MBEC was lower when exposure time was 5 days than 1 day in 11 of 12 antimicrobial/microorganism pairs. The MBEC range for these 11 pairs on Day 1 was 4000 to > 8000 μg/mL and on Day 5 was < 250 to 8000 μg/mL. MBEC for tobramycin/P. aeruginosa was 2000 μg/mL on Day 1 and ≤ 250 μg/mL on Day 5, and for E. coli, 125 μg/mL on Day 1 and ≤ 62.5 on Day 5.
conclusionsAlthough antimicrobial susceptibility was lower for longer exposure times in the microorganisms we studied, confirmation is required for other pathogens. Clinical Relevance One-day MBEC assays may overestimate the local antimicrobial levels needed to kill organisms in biofilm if local levels are sustained at MBEC or above for longer than 24 hours. Future studies are needed to confirm that antimicrobial levels achieved clinically from local delivery are above the MBEC at relevant time points and to confirm that MBEC for in vitro microorganisms accurately represents MBEC of in vivo organisms in an clinical infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.